A. Suisse, A. G. Dans-notre-société-hier, F. Caputo, E. Capristo, G. Colombo et al., Disponible sur: http://www.sfa-ispa.ch/DocUpload/alcool_societe Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence, Alcohol, 2011.

A. G. Leggio, L. Abenavoli, L. Agabio, R. Caputo, F. Capristo et al., Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam, Am. J

A. G. Leggio, L. Ferrulli, A. Cardone, S. Bedogni, G. Caputo et al., Doseresponse effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial, Alcohol Alcohol. juin, vol.46, issue.3, pp.312-319, 2011.

A. France and B. G. Tabaa-y, Al-Anon : aide à l'entourage de l'alcoolique. [cité 25 nov 2015, Disponible sur, p.146

A. Assistance, Alcoolisme, alcool, dépendances, Alcool assistance, alcoolique [Internet

A. Etude, abstinence des patients alcoolo-dépendants [Internet]. 2012 Disponible sur: http://www.baclofene.org/wp- content/uploads World Health Organization, ALPADIR_ETUDE_DP_14nov2012.pdf ALWAN A, World Health Organization. Global status report on non-communicable diseases 2010, p.162, 2010.

A. Olivier, . Le-dernier, and . Verre, Barcelone: Pocket, p.349, 2008.

. American-psychiatric-association, Desk reference to the diagnostic criteria from DSM-5, American Psychiatric Association, vol.2013, p.395

. Disponible-sur, Recommandation temporaire d'utilisation du baclofene dans l'alcoolo-dependance - 5478accaf69e1a0f97987c9eeb9b9347, R0234681.htm ANSM

A. Baclofenepdf, A. Rf, D. Moak, L. Waid, P. Latham et al., Disponible sur: http://ansm.sante.fr/var/ansm_site/storage/original/application/95b2ebc9062e9a86c1b76e0593 2af34a Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebocontrolled trial, Am J Psychiatry. nov, vol.156, issue.11, pp.20151758-64, 1999.

A. N. Birkmayer-w, W. Danielczyk, and G. Weiler, Disponible sur: http://www.anpaa.asso.fr/lanpaa/qui-sommes- nous/histoire AUBIN H-J. De l'alcoolisme aux troubles liés à l'utulisation de l'alcool : cheminement du DSM et de la classification internationale des maladiesOn the objectivization of the myotonolitic effect of an aminobutyric acid derivative (Ciba 34647-Ba)], pp.7-9, 1967.

B. C. , A. M. Magro, A. Muñoz, A. Amate, and J. , Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review, Addiction. juill, vol.99, issue.7, pp.811-839, 2004.

B. Sm, M. Rosenzweig, and N. Watson, Psychobiologie, de la biologie du neurone aux neurosciences comportementales, cognitives et cliniques. 1ère édition. Bruxelles: de boeck, p.739

B. Jcm, Aspects neurologiques de l'addiction. 2ème édition

C. F. Addolorato, G. Lorenzini, F. Domenicali, M. Greco, G. Del et al., Gammahydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study, Drug and Alcohol Dependence. 1 mai, vol.70, issue.1, pp.85-91, 2003.

C. J. Disponible-suralcool, A. R. Checinski, K. Croop, R. Drummond, D. Farmer et al., A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse, Alcohol Alcohol. déc, vol.35, issue.6, pp.587-93, 2000.

C. J. Gough, K. Falkowski, W. Kershaw, P. Hore, B. Mehta et al., Disulfiram treatment of alcoholism, Br J Psychiatry. juill, vol.161, pp.84-93, 1992.

. Disponible-sur, cnrs.fr/articles/quand-le-foetus-trinque DE BEAUREPAIRE R. Traitement de l'alcoolisme par le baclofène, Psychiatr Sci Hum Neurosci. 14 janv, vol.9, issue.1, pp.1-6, 2011.

D. Beaurepaire-r, Suppression of Alcohol Dependence Using Baclofen: A 2-Year Observational Study of 100 Patients, Frontiers in Psychiatry, vol.3, p.103, 2012.
DOI : 10.3389/fpsyt.2012.00103

D. Beaurepaire-r and S. , Vérités et mensonges sur le baclofène la guérison de l'alcoolisme. Première édition, p.187

D. Beaurepaire and J. P. , La RTU est-elle en train d'assassiner le baclofène ? Le Flyer, sept, issue.60, 2015.

D. P. Durand, D. , L. Jeunne, and C. , Guide pratique des médicaments Maloine. 30e édition. Lonrai: Maloine, p.1892, 2011.

E. Fatimy-r, F. Miozzo, L. Mouël, A. Abane, R. Schwendimann et al., Heat shock factor 2 is a stress-responsive mediator of neuronal migration defects in models of fetal alcohol syndrome, EMBO Molecular Medicine, vol.6, issue.8, pp.1043-61, 2014.
DOI : 10.15252/emmm.201303311

F. Faculté-de-rennesppt, . Rk, L. Branchey, and D. Brightwell, Physiopathologie des addictions Disponible sur: https://facmed.univ- rennes1, 2008.

F. Rk and R. Hp, Disulfiram for the treatment of alcoholism. An evaluation in 128

G. Jc, A. Kampov-polevoy, R. Gallop, L. Kalka-juhl, and B. Flannery, Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial, Alcohol. Clin. Exp. Res. nov, vol.34, issue.11, pp.1849-57, 2010.

G. J. Caso, C. Arias, F. Gual, A. Sanahuja, J. Ramírez et al., A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial, Alcohol. Clin. Exp. Res. sept, vol.26, issue.9, pp.1381-1388, 2002.

. Guerin-s, A. Laplanche, A. Dunant, and C. Hill, Alcohol-attributable mortality in France, European Journal of Public Health, vol.23, issue.4, pp.588-93, 2013.
DOI : 10.1093/eurpub/ckt015

. Disponible-sur, CT- 12915_SELINCRO_PIC_INS_Avis3_CT12915.pdf INPES. INPES -Les campagnes de communication [Internet]. Institut n ational de prévention et d'éduction pour la santé, Disponible sur, p.2013, 2015.

. Institut-de-veille-sanitaire and L. Møller, Numéro thématique?L'alcool, toujours un facteur de risque majeur pour la santé en France Special issue?Alcohol remains a major risk factor for health in France, Disponible surBEH-alcool_2013.pdf Institut National de la Santé et de la Recherche Médicale (France). Alcool. Paris: INSERM, p.564, 2003.

K. C. Costagliola, D. Autran, and B. , Tackling latency as a barrier to an HIV cure: what next? The Lancet HIV, déc, vol.2, issue.12, pp.504-509, 2015.

K. B. and W. Iq, Cerveau et comportement. 2ème édition. Bruxelles: de boeck, 1013.

L. Croix-bleue, La croix bleue [Internet]. [cité 25 nov 2015, Disponible sur

L. Moniteur and D. Pharmacies, Dépendance à l'alcool, 2015.

L. Varet, B. Clauvel, J. Lefrère, F. Bezeaud, A. Guillin et al., Hématologie et transfusion. 2e édition. Issy-les-Moulineaux: Masson, p.406, 2008.

L. Ss, T. Vos, A. Flaxman, G. Danaei, K. Shibuya et al., A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions: a systematic analysis for the Global Burden of Disease Study, pp.2224-60, 1990.

M. P. Serra, S. Vacca, G. Orrù, A. Pes, D. Agabio et al., Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats, Alcohol. juill, vol.36, issue.3, pp.161-169, 2005.

. Mann-k, P. Lehert, and M. Morgan, The Efficacy of Acamprosate in the Maintenance of Abstinence in Alcohol-Dependent Individuals: Results of a Meta-Analysis, Alcoholism: Clinical & Experimental Research, vol.21, issue.1
DOI : 10.1016/S0140-6736(96)91682-7

M. Ca, O. Geisel, P. Pelz, V. Higl, J. Krüger et al., High-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized

O. Mondiale-de and L. Santé, Global status report on alcohol and health, Geneva: World Health, p.376, 2014.

O. Mondiale-de-la-santé, P. Anderson, L. M. , G. Gauden, P. Fm et al., Alcohol in the European Union -Consumption, harm and policy approaches [Internet]. 2012 [cité 15 sept 2015] Disponible sur Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol, Alcohol Alcohol. mars, vol.30, issue.2, pp.239-286, 1995.

. France, Bull Epidémiol Hebd, Bulletin Epidémiologique Hebdomadaire, p.13, 2015.

-. , P. Dong, Y. Ito, W. Yanagawa, Y. Shigemoto et al., Selective gating of glutamatergic inputs to excitatory neurons of amygdala by presynaptic GABAb receptor, févr, vol.2425, 2015.

P. I. Verbanck, P. , L. Bon, O. Gavrilovic, M. Lion et al., Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebocontrolled dose-finding study, Br J Psychiatry. juill, vol.171, pp.73-80, 1997.

P. P. Rigole, H. Blanc, and F. , Alcoolo-dépendance : diagnostic et traitement. La Revue de Médecine Interne, avr, vol.29, issue.4, pp.297-304, 2008.

P. V. Popovic, I. Ivic, B. Stevanovic, and Z. , Subcutaneous implantation of Disulfirameffective therapy or placebo? European Psychiatry, avr, vol.23, issue.2, pp.317-174, 2008.
DOI : 10.1016/j.eurpsy.2008.01.1092

R. L. Alexandre-dubroeucq, C. De-beaurepaire, R. , L. Jeunne, C. Jaury et al., Abstinence and « low-risk » consumption 1 year after the initiation of high-dose baclofen: a retrospective study among « high-risk » drinkers, Alcohol Alcohol. août, vol.47, issue.4, pp.439-481, 2012.

R. Dc and A. Mm, Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure, Psychopharmacology (Berl.). juin, vol.131, issue.3, pp.271-278, 1997.

S. Cr, N. Larocca, B. Giesser, and L. Scheinberg, High-dose oral baclofen: experience in patients with multiple sclerosis, Neurology. nov, vol.41, issue.11, pp.1829-1860, 1991.

S. Française-d-'alcoologie, Mésusage de l'alcool dépistage, diagnostic et traitement Recommandations de bonne pratique, 2015.

V. Jr, A. Alterman, M. Hayashida, O. Brien, and C. , Naltrexone in the treatment of alcohol dependence, Arch. Gen. Psychiatry. nov, vol.49, issue.11, pp.876-80, 1992.